Call to arrange a consultation
+1 416 777 0888
Search the site
Amgen Canada Inc. et al v. Sandoz Canada Inc.
2022
T-1838-22
Pending
New PM(NOC) Regulations
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,589,765, 2,589,921, 2,701,778, 2,741,312 and 2,873,044 (carfilzomib).
Counsel to:
Sandoz Canada Inc.
The decision is reported
here.
Meet the team
